NEW YORK, July 26, 2019 /PRNewswire/ — As technology evolves our world, it’s making the globe seem smaller and smaller every day. The trend of globalization is affecting nearly every industry, and the clinical trials industry is no exception. However, as clinical trials expand away from their home shores, new challenges are bound to arise. fishbat discusses 4 significant challenges that global clinical trials and patient recruitment service providers are facing in this new globalized industry.
While there are many challenges associated with global clinical trials, they are nevertheless increasing in numbers consistently in the clinical trials industry. Opening up the clinical trial industry to a wider, global pool of patients has many benefits for the scientific medical community and can greatly benefit the global study participants and the study centers alike. Don’t shy away from the challenges and instead, face them head on!
About fishbat
fishbat is a full-service digital marketing company specializing in clinical trial advertising. The fishbat team takes a holistic business approach to their clients’ digital marketing programs but understanding the importance of business principles just as well as the nuances of the latest digital technologies. fishbat offers every digital marketing service available from digital marketing research and planning to clinical trial brand development to website and asset creation through social media management and search engine optimization programs – all custom calibrated for both B2B and B2C businesses.
View original content:http://www.prnewswire.com/news-releases/fishbat-discusses-4-challenges-global-clinical-trials-face-300887560.html
SOURCE fishbat
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…